First Report of Response to Tarlatamab in a Patient With Histologic-Transformed SCLC From ALK-Rearranged NSCLC: Case Report
Year: 2025
Type: article
Study design: Case Report
Abstract: -rearranged NSCLC with transformation to SCLC, who has progressed on several lines of therapies and successfully treated with tarlatamab to elicit and maintain clinical benefit, including intracranial response.
Authors: Kaiwen Wang, Ceylan Altintas Taslic, Patricia de Groot, Mitchell A. Parma, Alvaro Guimaraes Paula, Melody Caranto, Komal Shah, Mukulika Bose, Cole Ruoff, Loukia G. Karacosta, Lauren A. Byers, Carl M. Gay, Jianjun Zhang, John V. Heymach, Bingnan Zhang
Institution: The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,000
OpenAlex ID: W7114902806